A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Cumberland Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
CPIX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -18.72 Med: 0.4 Max: 113.04
Current: -8.03
During the past 13 years, the highest Debt-to-EBITDA Ratio of Cumberland Pharmaceuticals was 113.04. The lowest was -18.72. And the median was 0.40.
CPIX's Debt-to-EBITDA is ranked worse than 100% of 687
companies
in the Drug Manufacturers industry
Industry Median: 1.66
vs CPIX: -8.03
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Cumberland Pharmaceuticals Debt-to-EBITDA Related Terms
Cumberland Pharmaceuticals Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CPIX vs INCR, CTOR, TLPH: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cumberland Pharmaceuticals Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cumberland Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Cumberland Pharmaceuticals (CPIX) has a Debt-to-EBITDA of -1.69 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cumberland Pharmaceuticals. According to the industry distribution chart, Cumberland Pharmaceuticals ranks #999999 out of 687 companies in the Drug Manufacturers industry.
Is Cumberland Pharmaceuticals' Debt-to-EBITDA too high?
Cumberland Pharmaceuticals' current Debt-to-EBITDA is -1.69. Based on the distribution chart, Cumberland Pharmaceuticals ranks #999999 out of 687 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cumberland Pharmaceuticals has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cumberland Pharmaceuticals' Debt-to-EBITDA compare to INCR and CTOR?
According to the Drug Manufacturers industry distribution chart, Cumberland Pharmaceuticals ranks #999999 out of 687 companies for Debt-to-EBITDA. This places Cumberland Pharmaceuticals in the lower half of its industry. The industry median Debt-to-EBITDA is 1.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.66, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cumberland Pharmaceuticals. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cumberland Pharmaceuticals's current Debt-to-EBITDA is -1.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cumberland Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cumberland Pharmaceuticals (CPIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.16, compared to a current price of $6.13 — trading 183.8% above its estimated fair value. The current Debt-to-EBITDA is -1.69. Cumberland Pharmaceuticals' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Cumberland Pharmaceuticals (CPIX), the current Debt-to-EBITDA is -1.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cumberland Pharmaceuticals (CPIX) Overvalued in 2026?
Based on GuruFocus' analysis, Cumberland Pharmaceuticals stock appears to be overvalued.
The current stock price of $6.13 is trading 183.8% above its estimated GF Value™ of $2.16.
GuruFocus considers Cumberland Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CPIX:
Debt-to-EBITDA: -1.69
GF Value™: $2.16 vs. price of $6.13 (183.8% above fair value)
No single metric tells the full story. See the CPIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
36GF Score
Get the complete analysis for CPIX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPIX has been successfully added to your 
